Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets, USP

Drug Facts

Active ingredients

Cetirizine HCl, USP 5 mg  
Pseudoephedrine HCl, USP 120 mg

Purpose

Antihistamine  
Nasal Decongestant

Uses

- temporarily relieves these symptoms due to hay fever or other upper respiratory allergies:
  - runny nose  
  - sneezing  
  - itchy, watery eyes  
  - itching of the nose or throat  
  - nasal congestion  
- reduces swelling of nasal passages  
- temporarily relieves sinus congestion and pressure  
- temporarily restores freer breathing through the nose

Warnings

Do not use

- if you have ever had an allergic reaction to this product or any of its ingredients or to an antihistamine containing hydroxyzine.  
- if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product.

Ask a doctor before use if you have

- heart disease  
- thyroid disease  
- diabetes  
- glaucoma  
- high blood pressure  
- trouble urinating due to an enlarged prostate gland
• liver or kidney disease. Your doctor should determine if you need a different dose.

Ask a doctor or pharmacist before use if you are taking tranquilizers or sedatives.

When using this product
• do not use more than directed
• drowsiness may occur
• avoid alcoholic drinks
• alcohol, sedatives, and tranquilizers may increase drowsiness
• be careful when driving a motor vehicle or operating machinery

Stop use and ask a doctor if
• an allergic reaction to this product occurs. Seek medical help right away.
• you get nervous, dizzy, or sleepless
• symptoms do not improve within 7 days or are accompanied by fever

If pregnant or breast-feeding:
• if breast-feeding: not recommended
• if pregnant: ask a health professional before use.

Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control Center right away.

Directions
• do not break or chew tablet; swallow tablet whole

<table>
<thead>
<tr>
<th>Group</th>
<th>Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>adults and children 12 years and over</td>
<td>take 1 tablet every 12 hours; do not take more than 2 tablets in 24 hours.</td>
</tr>
<tr>
<td>adults 65 years and over</td>
<td>ask a doctor</td>
</tr>
<tr>
<td>children under 12 years of age</td>
<td>ask a doctor</td>
</tr>
<tr>
<td>consumers with liver or kidney disease</td>
<td>ask a doctor</td>
</tr>
</tbody>
</table>

Other information
• store between 20° to 25°C (68° to 77°F)
• do not use if inner safety seal is open or torn
• see side panel for batch number and expiration date

Inactive ingredients
hydroxyethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium stearate, microcrystalline cellulose, stearic acid, titanium dioxide
Imprinting Ink Contents: ammonium hydroxide, iron oxide black, isopropyl alcohol, N-butyl alcohol,
Questions?

Call toll free 1-800-818-4555 weekdays

Principal Display Panel - Showbox

LEADER

NDC 70000-0163-1

Allergy Relief-D
Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets, USP
5 mg/120 mg
Antihistamine | Nasal Decongestant
Original Prescription Strength

COMPARE TO ZYRTEC-D® 12 HOUR
active ingredients*

12 Hour Relief of:
• Sinus Pressure • Nasal Congestion
• Runny Nose • Sneezing
• Itchy, Watery Eyes
• Itchy Throat or Nose

24 EXTENDED-RELEASE TABLETS (4 blister cards of 6 tablets each)
# Allergy Relief-D

Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets, USP 5 mg/120 mg

**Antihistamine | Nasal Decongestant**

Original Prescription Strength

## Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>HUMAN OTC DRUG</th>
<th>Item Code (Source)</th>
<th>NDC: 70000-0163</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route of Administration</td>
<td>ORAL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>CETIRIZINE HYDROCHLORIDE (UNII: 64O047KTOA) (CETIRIZINE - UNII:YO7261ME24)</td>
<td>CETIRIZINE HYDROCHLORIDE</td>
<td>5 mg</td>
</tr>
<tr>
<td>PSEUDOEPHEDRINE HYDROCHLORIDE (UNII: 6V9V2RYJ8N) (PSEUDOEPHEDRINE - UNII:7CUC9DD9BF)</td>
<td>PSEUDOEPHEDRINE HYDROCHLORIDE</td>
<td>120 mg</td>
</tr>
</tbody>
</table>

## Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>HYDROXYPROPYL CELLULOSE (TYPE H) (UNII: RF2ET671P)</td>
<td></td>
</tr>
</tbody>
</table>
**Product Characteristics**

<table>
<thead>
<tr>
<th>Color</th>
<th>WHITE</th>
<th>Score</th>
<th>no score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shape</td>
<td>ROUND (circular)</td>
<td>Size</td>
<td>9 mm</td>
</tr>
<tr>
<td>Flavor</td>
<td></td>
<td>Imprint Code</td>
<td>9 15</td>
</tr>
<tr>
<td>Contains</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Packaging**

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:70000-0163-1</td>
<td>24 in 1 CARTON; Type 0: Not a Combination Product</td>
<td>05/02/2017</td>
<td></td>
</tr>
</tbody>
</table>

**Marketing Information**

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA</td>
<td>ANDA090922</td>
<td>05/02/2017</td>
<td></td>
</tr>
</tbody>
</table>

**Labeler** - Cardinal Health (097537435)

**Registrant** - Sun Pharmaceutical Industries Limited (650172430)

**Establishment**

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sun Pharmaceutical Industries Limited</td>
<td></td>
<td>650445203</td>
<td>ANALYSIS(70000-0163) , MANUFACTURE(70000-0163)</td>
</tr>
</tbody>
</table>

Revised: 7/2017